Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays
Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...
AFP5h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
pharmaphorum15m
Exploring the future: Opportunities and challenges in cell and gene therapy for rare diseases
In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...
FDA green lights new painkiller
The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...
News Highlights: Top Company News of the Day - Friday at 1 AM ET
The company has heavily advertised AI features since the latest iPhones were released in September. Revenue rose 10% from a year ago to $9.5 billion. The shift occurs after many brands cut their ...
These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...